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OBJECTIVES: As chronic asthma in Finland is mainly treated
by general practitioners limited data is available on the natural
course of the disease. We evaluated the burden of this disease on
health care providers and the adherence to accepted treatment
protocols in this retrospective study. METHODS: We examined
the complete medical records of 50 asthmatic patients obtained
from all reported health care providers (2000–05). Providers
were registered according to site, location and personnel
involved. Contact was speciﬁed as a visit, emergency room (ER)
visit, phone call, prescription or procedure. The primary cause
of contact labeled the event as asthma-(AR) or non-asthma
related (NAR) according to clinical speciﬁcations. Data on all
asthma medication and adverse drug reactions (ADR) were col-
lected from medical records. RESULTS: Asthma was the main
reason for contact with health care providers in 961 (52%) of
all 1847 events recorded. The number of events ranged from four
to 94 per patient with a mean of 23. The type of contact was
typically a visit (61%) and provider a general practitioner. ER
visits were found in 40% of the patients, 64% of these were AR.
Longest period for hospitalization due to asthma was 23 days,
but no intensive care treatment was necessary. All patients had
short-acting beta-agonists and inhaled corticosteroids (CS) as
ﬁrst-line medication and 32% had no need for additional treat-
ment during the follow-up. Long-acting beta-agonists were used
by 55% at some point and 48% of all patients had acute exac-
erbations treated with oral CS. ADR were observed in 57% of
all patients and in 2.5% of all asthma-related events. An alter-
ation to medication was done in 45% of asthma-related visits.
CONCLUSIONS: Reliable data were obtained from this evalu-
ation of patient records regarding disease history. Non-respon-
ders can be identiﬁed as well as those prone to ADR.
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OBJECTIVES: The human impact (symptoms, quality of life and
overall wellbeing) of severe persistent allergic asthma is great
owing to the chronic nature of the disease and the burden of
exacerbations. We undertook the present study to examine the
human impact of severe persistent allergic asthma in patients
who remain inadequately controlled and how human impact
varies according to disease severity. METHODS: Patients with
asthma were enrolled in a large cross-sectional observational
study and were stratiﬁed by disease severity (Global Initiative for
Asthma [GINA] classiﬁcation). Patients were recruited in the UK,
Germany, France, Italy and Spain by physicians who were asked
to recruit the next 6 patients presenting with asthma. Human
impact was assessed using an extensive questionnaire, which
included the EuroQol EQ-5D. RESULTS: Out of a total of 2802
patients, 1306 (47%) had allergic asthma. Of these, 985 patients
(mean age 36.4 years; mean FEV1 89.6% predicted normal) had
the following GINA asthma severity classiﬁcations: mild inter-
mittent (3.2%); mild persistent (7.6%); moderate persistent
(11.7%) and severe persistent (77.5%). Overall, 29% (n = 219)
patients with severe persistent allergic asthma were inadequately
controlled. These patients had more symptoms—including bron-
chospasm, nocturnal symptoms, difﬁculty breathing when
resting and cough—than patients with moderate disease (all p <
0.01). Other human impact factors that were adversely affected
included impaired mobility, nocturnal disturbance and impaired
lifestyle (all p < 0.01 vs. moderate asthma). Quality of life was
impaired in these patients: the mean EQ-5D score was 0.808 for
severe persistent asthma that was inadequately controlled vs.
0.938 for moderate asthma (p < 0.01). CONCLUSIONS: The
human impact of asthma increases according to disease severity;
human impact is greatest in patients with severe persistent aller-
gic asthma who remain inadequately controlled. Treatment
options that aim to achieve adequate control will contribute to
improved management of patients with severe persistent allergic
asthma.
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RESPIRE: is a quasi-experimental study on the impact of an inte-
grated primary care interventions program on asthma related
quality of life (QoL) among individuals aged 12 to 45 years who
have asthma. One of the aims of the RESPIRE interventions is
to improve QoL through a better asthma control. However,
before implementing the interventions, the assumption of a pos-
itive correlation between asthma control and QoL needed to be
tested. OBJECTIVE: The current study aimed at assessing,
among RESPIRE participants, the relationship between asthma
control and QoL. METHODS: This is a cross-sectional analysis
of baseline characteristics of individuals recruited by community
pharmacists who identiﬁed among their clients those aged 12 to
45 years, who had a previous diagnosis of asthma and were using
a short-acting beta-2 agonist more than three times a week or
an inhaled corticosteroid. Participants were interviewed on
socio-demographic characteristics, social support and perceived
health. Asthma control and QoL were measured using the ques-
tionnaires developed by Juniper et al. We assessed the correla-
tion between asthma control and QoL scores using multivariate
linear regression analysis adjusting for age, sex, education,
employment status, income, social support and perceived health
status. RESULTS: A total of 220 individuals were interviewed.
Their mean scores were 5.41/7 for QoL and 1.45/5 for asthma
control (a higher QoL score indicates a higher QoL, while a
higher asthma control score reﬂects a lower asthma control). An
improvement in QoL was signiﬁcantly associated with an
increase in asthma control (correlation coefﬁcient: -0.785 (p <
0.0001)). CONCLUSIONS: These ﬁndings conﬁrm the theoret-
ical basis of our approach. In RESPIRE, interventions aiming at
improving asthma control should translate in an improvement
in QoL.
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